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Ultrasound responsive Mesoporous Silica Nanoparticles for 
biomedical applications
Miguel Manzanoa,b  and María Vallet-Regí a,b*
Nanotechnology, which has already revolutionised many technological areas, is expected to transform life sciences. In this 
sense, nanomedicine could address some of the most important limitations of conventional medicine. In general, 
nanomedicine include three major objectives: (1) trap and protect a great amount of therapeutic agents; (2) carry them to 
the specific site of disease avoiding any leakage; and (3) release on-demand high local concentrations of therapeutic agents. 
This feature article will make special emphasis on mesoporous silica nanoparticles that release their therapeutic cargo in 
response to ultrasound. 
1. Introduction
Nanomedicine, the application of nanotechnology to medicine, has 
attracted the attention of the research community in the last few 
years. Among all the available nanomaterials, nanoparticles (NPs) for 
drug delivery are the most investigated due to the possibility of 
transporting and releasing therapeutic agents in a controlled 
manner, overcoming many limitations of conventional therapies.1,2
Researchers in biotechnology have developed many different types 
of NPs, both organic and inorganic. Among them, those NPs made of 
silica have become very popular due to their robustness. Silica 
quantum dots (C-dots from Cornell University) are currently under 
evaluation in clinical trials in patients with metastatic melanoma for 
cancer imaging.3 However, the adsorption capacity of C-dots is 
limited, which restricts their use as drug delivery systems. 
Mesoporous Silica Nanoparticles (MSNs) are also made of silica but 
with a porous structure that allows introducing therapeutic agents in 
their network of cavities. Additionally, it is possible to design MSNs 
with stimuli-responsive behaviour, which allows tailoring the release 
profiles with spatial, temporal and dosage control. The present 
Feature Article will focus on the recent developments on MSNs 
responsive to ultrasound.
2. Mesoporous materials
In the late 1980s and early 1990s, the catalyst industry was 
demanding porous materials with larger pores than those from 
zeolites. Consequently, the pioneering reports on the synthesis of 
mesoporous silica materials (MSMs) were published.4,5,6 This new 
family of materials was characterised by an ordered distribution of 
the pores, which presented homogeneous sizes within a range of 2 
and 10 nm; a great pore volume, ca. 1 cm3/g, and a huge surface area, 
up to 1000 m2/g. Those characteristics made MSMs potentially useful 
in those processes that might require the adsorption of molecules. In 
fact, the number of applications has grown exponentially since the 
early 1990s, as revealed by the number of publications on 
Mesoporous Materials in the last few years (Fig. 1). 
Figure 1. Number of publications on Mesoporous Materials in the last few 
years (more than 130,000 publications). Source: Google Scholar.
2.1 Synthesis
The synthesis of MSMs is based on the sol-gel process through the 
condensation of silica precursors around a template formed by self-
assembled surfactant molecules. Then, the template removal 
through thermal methods or solvent extraction leads to a material 
full of network of cavities. Obviously, the nature and chemical 
composition of the surfactant molecules together with the 
concentration and temperature of the synthetic process will 
influence on the shape and size of the micelles formed (different 
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liquid crystal mesophases and morphologies) and, consequently, on 
the mesostructure of the MSM (e.g., disordered, wormhole-like, 
hexagonal, cubic, and lamellar mesophases) .7 This is one of the most 
interesting aspects of this synthetic path, because controlling the 
micelles formation is possible to control the final mesostructure of 
the porous material, which would determine the physico-chemical 
properties of the product.
There are many different types of MSNs that have been produced 
following the above mentioned synthetic route. Although the 
synthesis of porous silica was originally patented in the 1960s, 
mesoporous silica materials were first described by Kuroda and co-
workers in 1990.4 Then, the subsequent work of the Mobil Oil 
Corporation Laboratories  brought the MSM family of mesoporous 
materials.5,6 During the last few years many different MSMs have 
been produced with uniform pore size and texture.8,9 As mentioned 
above, the current synthetic procedures of MSMs are normally based 
on the use of surfactants as structure directing agents. Those 
synthesis methods include the sol-gel process, microwave synthesis, 
hydrothermal synthesis, template synthesis, modified aerogel 
methods, soft and hard templating methods, and fast self-
assembly.10 
2.2 Funtionalisation
As it has been mentioned above, the adsorption of molecules is one 
of the most promising applications of MSMs. Adsorption is a surface 
phenomenon strongly influenced by the potential host-guest 
interaction. In this sense, the chemistry of the surface of MSMs can 
be easily tuned through the functionalisation of the silanol groups 
present at the surface.11 In fact, there are many surface modification 
strategies that allow the covalent attachment of almost any 
functional group.12 The host-guest interaction can be designed to 
favour certain processes, such as slow down the cargo release, 
maximise the loading capacity, etc. This great versatility has fuelled 
the use of MSMs for many different applications, such as catalysts, 
sensors, optical products, environmental applications and 
biomedicine.13,14,15
2.3 Biomedical applications
In 2001, taking into account the great adsorption capabilities of 
MSMs and the possibility to control the host-guest interactions, prof. 
Vallet-Regí proposed MSMs as drug delivery systems for the first 
time.13 Since then, a great variety of therapeutic agents have been 
loaded into MSMs for different biomedical applications, such as drug 
delivery, imaging or theranostics.16,17,18,19,20,21,22,23 
3. Mesoporous silica nanoparticles for drug 
delivery
Although MSM were initially proposed as bulk materials for drug 
delivery, it did not take very long to develop nanoparticles with the 
same textural characteristics. The morphology and dimensions of the 
produced materials can be controlled through the kinetics of the sol-
gel chemistry, such as reaction temperature, water content, or pH. 
In fact, it is possible to tailor the size, mesostructure and morphology 
of the produced material through the careful control of the template 
self-assembly and silica condensation rate.24 They were called 
mesoporous silica nanoparticles and presented diameters between 
100 and 150 nm.25,26,27,28 MSNs were initially reported by Cai,25 
Mann26 and Ostafin27 research groups. Then, Victor Lin popularised 
the term mesoporous silica nanoparticles and their use for drug 
delivery applications.28 The synthetic procedure of MSNs is based on 
small modifications to the above mentioned MSMs synthetic path, 
such as the pH of the reaction mixture, the type of surfactants and 
co-polymers employed and the concentration and sources of the 
silica precursors employed.24 Those nanoparticles were originally 
designed for many different applications such as adsorption,29 
catalysis,30 chemical separations,31 imaging,32 targeting,33 drug 
delivery34 and biosensing.35 Similarly, the use of MSNs as stimuli-
responsive drug delivery systems was proposed by prof. Lin using 
different agents to cap the pore entrances, such as quantium dots,28 
gold nanoparticles,36 iron oxide nanoparticles37 or dendrimers.35 
Regarding their application as drug delivery systems, MSNs provide 
a new therapeutic armamentarium able to address some of the most 
important limitations of conventional medicine, such as: lack of 
specificity, narrow window of efficacy, low drug solubility and/or 
stability, non-adequate pharmacokinetic profiles and potential side 
effects.38 In this sense, MSNs aim at transporting and releasing 
therapeutic compounds to diseased tissues in a selective and 
controlled manner.
Since MSNs were proposed as drug nanocarriers, there has been an 
increase in the publications about smart MSNs for the potential 
treatment of different diseases (Fig. 2).39 The reasons for such a 
success as nanovehicles could be found on their unique properties, 
such as: great textural characteristics to load a great amount of 
molecules, tuneable pore shape and pore diameter that allow 
loading a great variety of cargo molecules, robustness and easy 
functionalisation that allow engineering versatile different 
nanocarriers using the same platform, and, last but not least, their 
biocompatibility at therapeutic dosages.40
Figure 2. Left: Number of publications on “Mesoporous Silica Nanoparticles” 
+ “Drug delivery” + “Responsive” in the last few years (source: Google 
Scholar). Top right corner: Transmission Electron Microscopy image of MSN. 
Bottom right corner: Schematic representation of the versatility of MSNs.
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3.1 Trap therapeutic cargo
The high drug loading capacity of MSNs permits using fewer 
nanocarriers for the treatment of certain diseases than other 
nanoparticles, which could be relevant from a toxicity point of view. 
Additionally, the cargo molecules inside the mesopore system of the 
MSNs are protected from harsh environmental factors such as 
enzymatic degradation. Back in 2010, we showed, for the first time 
direct evidence of the drug confinement into the inner part of the 
pore channels through Scanning Transmission Electron Microscopy 
with spherical aberration correctors incorporated (Fig. 3).41 Up to 
then, the presence of drugs into the pores was characterised through 
the sum of indirect techniques, such as nitrogen adsorption42 or 
thermogravimetry.43 The high resolution microscopy allowed the 
determination of the chemical composition of both matrix walls and 
pore area, which permitted the qualitative determination of the 
presence of molecules into the inner area of the mesopores. Thus, 
MSNs meet the first objective of any given nanomedicine: trapping 
and protecting a great amount of therapeutic cargo. 
Figure 3. Schematic representation of drug loading into the pores of MSNs 
(top). [100] STEM image, perpendicular to the mesopores with the 
corresponding image intensity profile of Si and O layers (bottom left corner). 
[001] STEM image, parallel to the mesopores with the corresponding image 
intensity profile of C and N layers (bottom right corner).
3.2 Transport therapeutic cargo
Regarding the second objective of any nanomedicine – transporting 
the therapeutic cargo to a specific site avoiding premature leakage – 
MSNs exhibit an excellent performance not only for hosting and 
protecting the cargo, but also for transporting it to the site of the 
disease. It is relatively easy to graft targeting agents to the external 
surface of MSNs to direct them towards diseased tissues. The 
potential cargo leakage during the journey might be avoided capping 
the pore entrances with responsive gatekeepers, as commented 
bellow. 
Most of the research on targeted delivery from MSNs has been 
dedicated to the fight against cancer. One of the reasons for that 
might be found in the fact that nanoparticles leak preferentially into 
tumour tissues when injected into the blood stream (passive 
targeting). They tend to accumulate in the tumour tissues thanks to 
their particular blood vessel architecture, in what is called Enhanced 
Permeation and Retention (EPR) effect, which improves the delivery 
of nanomedicines to tumours.44,45   
However, the EPR effect offers less than a 2-fold increase in 
nanoparticle accumulation in comparison with normal organs, which 
might result in therapeutic concentrations that are not enough for 
treating some cancers.46 A possible alternative that has been widely 
explored consists in decorating the surface of the nanocarriers with 
ligands that present high affinity towards some specific membrane 
receptors overexpressed in tumour cells, in what is called active 
targeting (Fig. 4). This approach has improved the selectivity of 
nanomedicines towards tumour cells and tissues, although it is not 
available yet in the market.47   
3.3 Release therapeutic cargo
Finally, the third objective of any nanomedicine should be releasing 
high local concentrations of therapeutic agents on-demand.48 It is 
important to keep control on the cargo release to avoid the 
premature release of transported cargo before reaching the targeted 
tissues. If that might happen, there would be a drastic reduction of 
the nanomedicine efficiency and several side effects might occur if 
the transported cargo is cytotoxic. This is of particular interest on 
MSNs, where it is relatively easy to introduce cargo molecules inside 
the mesoporous system, but it is also relatively easy for those 
molecules to diffuse out. Thus, it is necessary to cap the pore 
entrances once the therapeutic cargo has been loaded. In this sense, 
MSNs present pores large enough to host many different therapeutic 
agents and yet small enough to be blocked by many different 
molecules working as pore caps. Those caps grafted at the pore 
entrances trap the loaded molecules avoiding their premature 
release, and only upon application of certain stimuli they might 
detach from the MSNs and trigger the cargo release. Recently, Zink 
and co-workers have categorised the different capping systems into 
three main groups: (1) Reusable caps, that work with a bulky capping 
molecule able to bind reversibly; (2) Completely reversible caps, that 
are based on the principle of reversal of affinity of a macromolecule 
with the shape of a ring twisted into a stem with two or more binding 
sites; and (3) Irreversible caps, that work through a chemical bond 
cleavage of the capping macromolecule, thus permanently 
separating from the host nanoparticle.49
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Figure 4. Schematic representation of surface functionalisation and cargo 
loading on MSNs for targeted drug delivery.
The stimuli employed to trigger the release from MSNs can be 
external or internal. External stimuli are those that can be remotely 
applied by the clinician, so they are under control at all times by the 
operator, they can be turned on and off as required and they can be 
applied locally into the site of the disease. Many examples of MSNs 
externally triggered can be found in the literature, such as magnetic 
field,50,51,52,53,54,55,56,57,58,59,60,61,62 light63,64,65,66,67,68,69,70,71,72 or 
ultrasound (US).73,74,75,76,77,78,79,80,81 On the other hand, internal 
stimuli are typical from the treated pathology. Among them, 
researchers on MSNs have employed pH (pH values of 6 or bellow 
can be found in tumours or lysosomes of 
cells),82,83,84,85,86,87,88,89,90,91,92,93,94,95 redox change potential (high 
concentration of antioxidants in the cytoplasm of tumour 
cells),28,96,97,98,99,100,101,102,103,104,105 overexpression of certain enzymes 
by tumour cells,106,107,108,108,109,110,111,112,113,114 or specific antibodies 
to tumour cells.115,116 All this stimuli-responsive MSNs platforms have 
been reviewed extensively somewhere else.38,117 
,118,119,120,121,122,123,124,125,126,127,128,129 This feature article will focus on 
the recent research carried out on ultrasound sensitive MSNs, one of 
the newest and most efficient stimuli employed with MSNs. 
4. Ultrasound sensitive mesoporous silica nano-
cariers
Although US has already been employed extensively in the clinic both 
for diagnostic and treatment,130,131 it is considered as one of the most 
promising triggers for drug delivery nanosystems.132 The reason for 
this interest relays on its capacity to non-invasively penetrate deep 
into the body without damaging healthy tissues.48  
4.1 Ultrasound features
Ultrasound is commonly produced using piezoelectric transducers 
than can transform an electric signal to a mechanic wave that is able 
to travel across a fluid. In the biomedical area, US has been employed 
for tumour ablation,133 treatment of Alzheimer´s disease,134  
hyperthermia generation,135 to cross the blood brain barrier,136  
immunostimulation,136 biomedical imaging136 and physical 
therapy.137 US is classified in three categories: low (<1MHz), medium 
(1-5MHz) and high (5-10MHZ) frequency US. On one hand, low 
frequency ultrasound displays an exceptional penetration depth in 
living tissues and is non-invasive, although it cannot be focused into 
a specific spot. On the other hand, medium and high frequency US 
show inferior tissue penetration and might damage living tissue as a 
consequence of the heat produced by the increased scattering. 
However, they can be focused and, consequently, the intensity at the 
focal point is higher. In this sense, curved transducers are employed 
to focus high intensity US (High Intensity Focused Ultrasound, HIFU) 
inside the body, which make possible to employ it for destruction of 
internal tumour tissues from the outside.
When applying US to living tissues, there are two types of effects: 
thermal and mechanical effects.135 On one hand, thermal effects are 
produced as a consequence of the US travel across tissue, in which 
part the Energy can be adsorbed by the tissue itself. This 
hyperthermia phenomenon can be employed in ablative therapies 
against cancer. On the other hand, among mechanical effects, 
cavitation is the most employed ultrasonic phenomenon in 
biomedicine, and it is based on the formation and oscillation of gas 
bubbles in a fluid.138 The bubbles are formed when mechanical waves 
from US interact with fluids, and their radius can oscillate around an 
equilibrium for several acoustic cycles. When working at high 
pressures, at certain US frequency and bubble radius, the bubbles 
can grow unstable leading to a violent collapse during compression, 
in what is called inertial cavitation. This phenomenon can produce 
extreme conditions locally in terms of high temperature and high 
pressure at the nanoscale level, which lead to the emission of bursts 
of light (called sonoluminescence) and reactive oxygen species from 
the pyrolysis of water. This inertial cavitation, together with thermal 
and/or mechanical effects from US, can be employed to induce or 
accelerate chemical reactions, in what is known as sonochemistry.139 
4.2 Ultrasound-responsive drug nano-carriers
The thermal,140 mechanical141 and chemical142 effects from US have 
been used for designing different US responsive drug delivery nano-
carriers, such as liposomes,132,143,144,145 micelles142,146,147 and 
polymeric nanoparticles.148 This sudden interest from the drug 
release scientific community relays on the characteristics that 
ultrasound can offer to the field, such as high tissue penetration 
capacity, non-invasiveness, portability, economy and spatiotemporal 
control. Consequently, US has turned to be one of the most 
promising options for controlled drug delivery devices in 
biomedicine.149,150,151 
4.3 Ultrasound-responsive MSNs
The first steps combining US with mesoporous silica were carried out 
using bulk mesoporous materials, such as MSM-41, whose pores 
were capped with poly(dimethylsiloxane). The application of US 
triggered the release of the previous loaded ibuprofen.152 It has been 
in the last few years, and motivated by the fast development of 
mesoporous silica nanoparticles,153 that US has been applied for 
triggering the release form MSNs (Fig. 5).154,155,156 
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Figure 5. Schematic representation of US triggered release from MSNs.
Comparing US with other external stimuli such as light or magnetic 
field applied to MSNs, we can conclude that there is a delay in terms 
of research and publications on US-responsive MSNs. This fact can be 
associated to the difficulty of designing and developing US-
responsive nanovalves at the pore entrances of MSNs. 
4.3.1 US induced release from MSNs
We recently developed a type of US-sensitive MSNs capping the 
pore entrances with a specially designed co-polymer.73 
Basically, the employed co-polymer presented a labile acetal 
group that could be cleaved through the application of US. 
Acetal removal resulted into a different polymer with different 
hydrophobicity. The transformation from hydrophobic to 
hydrophilic leaded to a change on the polymer conformation 
and triggered cargo release. One of the interesting features of 
our system is that one of the components provides thermo-
responsive behaviour in a way that before US irradiation, the 
pores would be capped at 37oC and opened at 4oC. Thus, it 
might be possible to produce the nanocarriers with the co-
polymer already grafted on the surface and then, in a separated 
step, the cargo can be loaded following a very simple 
procedure: place a MSNs solution into a fridge, add the drug 
solution and then place the loaded MSNs at 37oC, so the pore 
entrances would be capped with the cargo already loaded. This 
fact would allow producing the MSNs in a lab and then send 
them to a clinic where they could be easily loaded with the 
selected therapeutic agent and applied to the patient. 
The designed US-responsive MSNs were checked not to be toxic 
in vitro. In this sense, none of the by-products from the 
nanocarriers before and after US irradiation affected the cell 
viability, ensuring their biocompatibility. Additionally, we 
checked the lack of damage into relevant biological molecules 
that might had been produced by the US exposure at 1MHz and 
15W.73
The US-responsive behaviour after cellular internalisation was 
retained, as observed in an intracellular release experiment, 
loading the MSNs with a fluorophore. Furthermore, when the 
MSNs were loaded with doxorubicin (anticancer drug) and 
evaluated with prostate cancer cells (LNCaP), a lack of cellular 
toxicity was observed before the US application, which meant 
that the pores were appropriately blocked avoiding any 
premature release. However, there was a dose-dependent 
toxicity to prostate cancer cells when the MSNs were exposed 
to US (Fig. 6), demonstrating their capacity to kill cancer cells 
only under the application of US.
Figure 6. Top: Fluorescence microscopy images of LNCaP prostate 
cancer cells with US-sensitive MSNs loaded with doxorubicin before US 
exposure (left) and after US exposure (right). Bottom: cell viability 
experiment in LNCaP cancer cells with different concentrations of 
doxorubicin loaded US-sensitive MSNs before US exposure (green) and 
after US exposure (red).
We then evaluated the opening mechanism of the US-sensitive 
MSNs in response to US, which theoretically could be due to 
thermal and/or mechanical effects. A new setting was 
developed, introducing a thermocouple in the sample holder to 
closely monitor the temperature and a passive cavitation 
detector to evaluate the mechanical acoustic cavitation. Three 
different frequencies (0.5, 1 and 3.3 MHz) of focused US were 
applied. We observed that applying certain intensity of inertial 
acoustic cavitation (mechanical effect) without significant 
temperature increase (thermal effect) was able to induce cargo 
release from MSNs. However, directly increasing the 
temperature of the sample or applying US with bulk heating but 
negligible cavitation were not capable of inducing cargo release. 
Thus, we were able to demonstrate that the mechanism to open 
the pore entrances of our US-sensitive MSNs was linked to 
acoustic cavitation, which ensures the safety of our system 
since the release will take place without increasing the 
temperature of the surrounding tissues.
In a different approach, US has been employed together with 
pH to develop a dual-responsive polydopamine-coated MSNs 
for controlled drug delivery.79 The polydopamine shell was 
grafted to the surface of the MSNs via self-polymerisation under 
alkaline conditions and the pores were loaded with doxorubicin. 
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Upon high-intensity focused ultrasound exposure, the cargo 
was released via a pulsatile fashion because of the ultrasonic 
cavitation effect.
Mesoporous silica nanoparticles have also been loaded with 
paclitaxel and folic acid functionalised Beta-cyclodextrin has 
been employed to cap the pores and as cancer targeting 
agent.80 This nanocarrier enhanced the cavitation effect and 
achieved rapid drug release under low-energy ultrasound, 
which was evaluated both in vitro and in vivo.
A multidrug delivery vehicle was also developed with MSNs 
functionalised with folic acid and encapsulated into a 
microbubble.78 Cytotoxicity and cellular uptake experiments we 
confirmed in vitro and the antitumor efficacy was corroborated 
in tumour bearing mice.
 
4.3.2 Targeting of US-responsive MSNs
One of the main objectives in nanomedicine for the potential 
treatment of cancer is the selective accumulation of the 
nanoparticles into the tumour areas without affecting healthy 
tissues. As it has been mentioned above, nanocarriers can be 
targeted and accumulated into tumours through either passive 
and/or active targeting. Both approaches are based on the 
circulation of the nanocarriers within the blood stream, so those 
nanoparticles must be stable in that physiological solution. In 
this sense, our previously developed US-sensitive MSNs 
presented a co-polymer on their surface that made them highly 
hydrophobic at physiological temperature which leaded to 
nanoparticle aggregation. Therefore, we covered those US-
sensitive MSNs with a layer of poly(ethylene glycol) (PEG) to 
prevent aggregation. Additionally, we grafted active targeting 
moieties through a series of chemical strategies to develop a 
PEGylated and modularly targeted US-responsive nanocarriers 
(Fig. 7).77 Those sets of chemical strategies had to be designed 
from scratch since previously reported methods were unable to 
produce this versatile US-responsive nanocarrier. Thus, we 
demonstrated that drug loaded RGD-targeted PEGylated US-
responsive MSNs produced significantly increased cancer cell 
killing only when exposed to US.   
Figure 7. Schematic representation of the RGD-targeted PEGylated US-
responsive MSNs produced.
Although MSNs might reach the targeted cancer tissue thanks 
to the EPR effect or the active targeting moiety, the treatment 
will not be completed until the cargo might be released into the 
cancer cells. Therefore, cells must uptake the nanoparticles and 
this might be enhanced by the presence of internalisation 
ligands (such as certain targeting agents) or positively charged 
moieties on the surface of the nanoparticles.157 This approach 
requires the development of hierarchical targeting strategies in 
which an internalisation ligand might be included in the 
formulation but hidden during the nanoparticles journey. In our 
lab, we developed this strategy using MSNs positively charged 
as the mechanism of internalisation, which was hidden by 
grafting PEG chains on the nanoparticle through a 
thermosensitive linker. Then, the application of US produced an 
increase of the temperature which provoked the disengage of 
the PEG chains from the nanoparticles and leaded to the 
exposure of the positive charges of the nanoparticles and, 
therefore, favouring the cellular uptake.76
Unfortunately, the presence of targeting agents on the surface 
of the nanoparticles to specific cancer cell receptors can lead to 
what is called the binding site barrier. The first line of cancer 
cells from a tumour will interact with the targeted nanoparticles 
in a very strong manner, leading to the retention of those 
nanoparticles in peripheral areas of the tumour mass and 
impeding their penetration to deeper areas of the tumour.158 
Additionally, large solid tumours normally present an elevated 
interstitial pressure, which limits the nanoparticle penetration 
deep into the tumour.159 A possible way to ensure the 
penetration of the MSNs into the mass might be through the 
use of ultrasound-induced inertial cavitation, which has been 
demonstrated to enhance the penetration into an agarose 
tissue model.75 Additionally, the combination of MSNs with 
submicrometric cavitation nuclei was observed to be more 
efficient way of nanoparticle penetration, which could be of 
interest in future applications of extravasation or tumour mass 
penetration of MSNs. 
5. Cellular vehicles for MSNs
Although the above mentioned approaches for targeting 
nanoparticles might had worked in the past with certain types 
of nanocarriers,160 the expected results in NPs targeting have 
not been achieved.161,162 That was the motivation to explore 
different alternatives to localise MSNs into tumours. One of 
those alternatives was based on using cells that migrate 
towards tumours to transport different nanoparticles to those 
tissues.163 Certain mesenchymal stem cells present inherent 
migratory properties in response to inflammation or injury, so 
they can be employed as cellular vehicles.164,165 Bone marrow 
and adipose tissue are the most common source of adult 
mesenchymal stem cells, but they present some drawbacks, 
such as highly invasive methods for extraction and inefficient 
isolation techniques. We have been working with an additional 
type of adult mesenchymal stem cells from the human placenta, 
decidua mesenchymal stem cells (DMSCs), that present some 
advantages, such as non-invasive and straightforward isolation 
techniques, low or non-immune response migratory properties 
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towards tumours.166,167 We took advantage of those properties 
to transport our US-responsive MSNs to tumour tissues, aiming 
the controlled release of the cytotoxic cargo only at the tumour 
environment.74 Our initial approach consisted on exploring the 
internalisation of MSNs into DMSCs, evaluating their potential 
toxicity and the retention time inside the cells.168 We found that 
MSNs with positive surface charge were better internalised 
than regular MSNs thanks to the electrostatic interaction with 
the negatively charged cell membrane (Fig. 8).
Figure 8. Fluorescence images of DMSCs with MSNs loaded: blue 
(nucleus), red (cytoplasm) and green (MSNs). (a) green channel, (b) 
green and blue channels, (c) green, blue and red channels.
Thus, the US-responsive MSNs were coated with 
poly(ethyleneimine) to favour their internalisation into the 
DMSCs. The US responsiveness of the nanocarriers was 
confirmed after the internalisation both in vitro and in vivo, as 
expected. The migration capacity towards tumours of the 
DMSCs loaded with the US-responsive MSNs was confirmed in 
an in vitro cell migration essay. Thus, we demonstrated that 
those cells can transport the loaded nanoparticles to a tumour 
tissue and, once in the these, the release of the cytotoxic cargo 
can be triggered with US affecting only at the cells present on 
the tumour environment.74
6. Conclusions and Future Perspectives
In summary, the outstanding properties of MSNs, such as high 
loading capacity, controllable particle size and shape, suitability 
for easy surface modification and biocompatibility, make them 
ideal candidates for drug delivery nanocarriers. In this feature 
article we have shown that using ultrasound for the spatio-
temporal controlled administration of potent drugs is a 
promising alternative for treating tumours. The administration 
of the transported drugs can be remotely triggered by the 
clinician, and the administered dose can be controlled with 
extremely high precision. It is this combination of selectivity and 
control in the release in a single nanocarrier, what provides a 
powerful tool in the fight against complex diseases such as 
cancer.
The future perspectives on the use of US with MSNs for 
biomedical applications are somehow linked to the ultrasound 
benefits and limitations. Among the former, the combination of 
portability, low cost and ease of use make US an affordable 
stimulus. Additionally, US combines a unique ability for soft 
tissue penetration without damaging it and very good spatial 
resolution, which can attain a spatial focus on the order of 10 
mm3. Those characteristics have made US the most widely used 
imaging technique in modern medicine. We have shown in this 
Feature Article that the technical issues of applying the US 
technology to MSNs can be solved, and it actually works. 
However, US present an important drawback when used in 
biomedicine: the blockage by bone and air. This means that this 
technology might be reduced to soft tissues areas, limiting its 
application in the clinic for drug delivery purposes.
From a more general perspective, and even though there has 
been a great progress in the design and development of MSNs 
for various biomedical applications, clinical translation has not 
been achieved yet. From our perspective, there are several 
challenges that should be solved before advancing to clinical 
trials, such as: the need for standardising the production 
methods to achieve reproducibility in the synthesis of 
mesoporous silica nanoparticles, good stability and 
dispersibility, or surface functionalisation protocols for clinical 
applications. Additionally, more biodistribution studies of MSNs 
should be carried out trying to reduce the variation in 
experimental design criteria for obtaining consistent results. In 
this sense, a recent perspective article written by World leaders 
in the nanomedicine area tries to stablish the fundamentals for 
understanding the bio-nano-interface in nanoparticles.169 The 
authors state that to overtake the experimental variability in 
nanomedicine research there should be a “minimum 
information standard” divided in three categories: (1) materials 
characterisation, (2) biological characterisation, and (3) details 
of experimental protocols. Thus, reproducibility could be 
improved and comparisons and meta analyses could be easily 
carried out. This would improve the level of communication 
between researchers in the field favouring the knowledge 
outcome from different in vivo experiments and, sooner than 
later, achieve the desired translation to the clinic. 
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